ETH-155008 is under clinical development by Shengke Pharmaceuticals (Jiangsu) and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ETH-155008’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ETH-155008 overview

ETH-155008 is under development for the treatment of relapsed and refractory B-cell non-Hodgkin lymphomas including diffuse large B-cell lymphoma, mantle cell lymphoma, high grade B-cell lymphoma (HGBCL), chronic lymphocytic leukemia (CLL), acute myelocytic leukemia (AML), follicular lymphoma, marginal zone B-cell lymphoma, waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), primary mediastinal b-cell lymphoma and unspecified indication. It acts by targeting cyclin-dependent kinase 4,6 (CDK4/6) and serine/threonine-protein kinase 1 and 3. It is administered through oral route.

For a complete picture of ETH-155008’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.